Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$295.20 +1.6%	$281.37	$253.30 ▼ $346.85	$158.52B	0.49	2.83 million shs	573,259 shs
ATVI Activision Blizzard	$94.42	$93.80	$70.94 ▼ $94.57	$74.29B	0.44	8.31 million shs	1 shs
HZNP Horizon Therapeutics Public	$116.30	$115.72	$60.03 ▼ $116.38	$26.63B	1.03	2.50 million shs	N/A
MSFT Microsoft	$492.35 +0.1%	$454.74	$344.79 ▼ $500.76	$3.66T	1.04	21.60 million shs	4.27 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+4.05%	+4.70%	+1.22%	-4.97%	-6.59%
ATVI Activision Blizzard	0.00%	0.00%	0.00%	0.00%	0.00%
HZNP Horizon Therapeutics Public	0.00%	0.00%	0.00%	0.00%	0.00%
MSFT Microsoft	-1.08%	+0.40%	+7.25%	+28.76%	+7.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.3174 of 5 stars	2.2	2.0	3.3	3.9	3.9	2.5	0.6
ATVI Activision Blizzard	0.8298 of 5 stars	0.0	0.0	2.5	2.1	0.6	1.7	0.6
HZNP Horizon Therapeutics Public	1.0105 of 5 stars	0.0	0.0	0.0	3.2	0.0	1.7	1.9
MSFT Microsoft	4.7015 of 5 stars	2.4	5.0	3.3	2.9	2.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.35	Hold	$307.82	5.95% Upside
ATVI Activision Blizzard	0.00	N/A	N/A	N/A
HZNP Horizon Therapeutics Public	0.00	N/A	N/A	N/A
MSFT Microsoft	2.88	Moderate Buy	$521.14	5.91% Upside

Current Analyst Ratings Breakdown

Latest ATVI, AMGN, HZNP, and MSFT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	MSFT Microsoft	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Positive ➝ Positive
6/27/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$328.00
6/26/2025	MSFT Microsoft	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$482.00 ➝ $530.00
6/25/2025	MSFT Microsoft	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$515.00 ➝ $600.00
6/25/2025	MSFT Microsoft	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$565.00 ➝ $585.00
6/24/2025	AMGN Amgen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/24/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00
6/13/2025	MSFT Microsoft	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$515.00 ➝ $565.00
6/11/2025	MSFT Microsoft	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$540.00 ➝ $605.00
6/4/2025	MSFT Microsoft	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/23/2025	MSFT Microsoft	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$525.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.67	$31.61 per share	9.19	$10.93 per share	26.58
ATVI Activision Blizzard	$8.71B	8.53	$3.38 per share	27.91	$24.59 per share	3.84
HZNP Horizon Therapeutics Public	$3.63B	7.34	$7.05 per share	16.49	$22.38 per share	5.20
MSFT Microsoft	$245.12B	14.92	$14.70 per share	33.48	$36.12 per share	13.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	26.51	13.58	2.53	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
ATVI Activision Blizzard	$1.51B	$2.73	34.59	24.09	2.61	24.87%	14.87%	10.78%	N/A
HZNP Horizon Therapeutics Public	$521.48M	$1.87	62.19	20.55	3.96	12.02%	20.46%	11.52%	N/A
MSFT Microsoft	$88.14B	$12.94	38.03	33.47	2.52	35.79%	32.74%	18.13%	7/29/2025 (Estimated)

Latest ATVI, AMGN, HZNP, and MSFT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q4 2025	MSFT Microsoft	$3.35	N/A	N/A	N/A	$73.79 billion	N/A
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
4/30/2025	Q3 2025	MSFT Microsoft	$3.22	$3.46	+$0.24	$3.46	$68.54 billion	$70.07 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.28%	N/A	86.86%	14 Years
ATVI Activision Blizzard	$0.99	1.05%	N/A	36.26%	1 Years
HZNP Horizon Therapeutics Public	N/A	N/A	N/A	N/A	N/A
MSFT Microsoft	$3.32	0.67%	N/A	25.66%	23 Years

Latest ATVI, AMGN, HZNP, and MSFT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/10/2025	MSFT Microsoft	quarterly	$0.83	0.71%	8/21/2025	8/21/2025	9/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	8.70	1.17	0.88
ATVI Activision Blizzard	0.17	4.66	4.66
HZNP Horizon Therapeutics Public	0.48	4.27	4.09
MSFT Microsoft	0.12	1.37	1.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
ATVI Activision Blizzard	81.93%
HZNP Horizon Therapeutics Public	80.37%
MSFT Microsoft	71.13%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
ATVI Activision Blizzard	1.08%
HZNP Horizon Therapeutics Public	2.20%
MSFT Microsoft	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.71 million	534.00 million	Optionable
ATVI Activision Blizzard	13,000	786.80 million	778.30 million	Optionable
HZNP Horizon Therapeutics Public	2,115	228.99 million	223.96 million	Optionable
MSFT Microsoft	228,000	7.43 billion	7.43 billion	Optionable

ATVI, AMGN, HZNP, and MSFT Headlines

Recent News About These Companies

Microsoft to lay off 9,000 employees, including deep cuts across Xbox division

1 hour ago | proactiveinvestors.com

Microsoft to cut about 4% of jobs amid hefty AI bets

1 hour ago | investing.com

Microsoft announces another mass layoff, thousands of workers affected

1 hour ago | techxplore.comT

Microsoft (MSFT) to Cut 9,000 Jobs Amid Restructuring Efforts

1 hour ago | gurufocus.com

Microsoft Stock (MSFT) Slips as Layoffs Come for Another 9,000 Employees

1 hour ago | tipranks.com

Microsoft (MSFT) Cuts Jobs in King Division Amid Broader Layoffs

1 hour ago | gurufocus.com

Microsoft to Lay Off 9,000 Employees in Global Workforce Restructuring

1 hour ago | gurufocus.com

Microsoft (MSFT) Announces Layoffs Impacting Global Workforce

1 hour ago | gurufocus.com

Microsoft announces another mass layoff, thousands of workers affected

...

1 hour ago | marketbeat.com

Microsoft cuts another 4% of its workforce, about 9,000 jobs, in continued push for efficiency

1 hour ago | geekwire.comG

Microsoft says it is laying off thousands of employees, its second mass layoff in months

...

2 hours ago | marketbeat.com

Microsoft Lays Off 9,000 Workers: Report

2 hours ago | barrons.com

Microsoft will lay off 9,000 employees, or less than 4% of the company

2 hours ago | techcrunch.comT

Microsoft's Rally Is Just Heating Up

2 hours ago | seekingalpha.com

Microsoft (MSFT) Recovered all of its Losses After the Q1 Earnings Report

2 hours ago | insidermonkey.com

Microsoft (MSFT) Gets $540 Price Target as AI and Azure Surge

2 hours ago | insidermonkey.com

Microsoft to lay off up to 9,000 employees in latest cut - The Seattle Times

2 hours ago | investing.com

DA Davidson Issues Positive Forecast for Microsoft (NASDAQ:MSFT) Stock Price

2 hours ago | marketbeat.com

Microsoft laying off about 9,000 employees in latest round of cuts

2 hours ago | cnbc.com

Microsoft to lay off as many as 9,000 employees, Seattle Times reports

2 hours ago | reuters.com

Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis

3 hours ago | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Microsoft Stock Holds Steady as AI Drives Workforce Shift
By Chris Markoch | June 23, 2025
View Microsoft Stock Holds Steady as AI Drives Workforce Shift
Is a Summer Slowdown Ahead for Microsoft Stock?
By Chris Markoch | June 11, 2025
View Is a Summer Slowdown Ahead for Microsoft Stock?
Microsoft Stock Near Peak, Pullback Seen as Opportunity
By Chris Markoch | June 4, 2025
View Microsoft Stock Near Peak, Pullback Seen as Opportunity
Microsoft-OpenAI Rift May Cap Stock Upside Potential
By Chris Markoch | June 18, 2025
View Microsoft-OpenAI Rift May Cap Stock Upside Potential
Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock
By Chris Markoch | July 2, 2025
View Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock

ATVI, AMGN, HZNP, and MSFT Company Descriptions

Amgen NASDAQ:AMGN

$295.20 +4.68 (+1.61%)

As of 11:01 AM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Activision Blizzard NASDAQ:ATVI

Activision Blizzard, Inc., together with its subsidiaries, develops and publishes interactive entertainment content and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Activision, Blizzard, and King. It develops and distributes content and services on video game consoles, personal computers, and mobile devices, including subscription, full-game, and in-game sales, as well as by licensing software to third-party or related-party companies that distribute Activision and Blizzard products. The company also maintains a proprietary online gaming service, Battle.net that facilitates digital distribution of content, online social connectivity, and the creation of user-generated content. In addition, it operates esports leagues and offer digital advertising content; and provides warehousing, logistics, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company's key product franchises include Call of Duty, World of Warcraft, Diablo, Hearthstone, Overwatch, Overwatch League, and Candy Crush. It serves retailers and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, and game specialty stores through third-party distribution and licensing arrangements. The company was founded in 1979 and is headquartered in Santa Monica, California.

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Microsoft NASDAQ:MSFT

$492.35 +0.30 (+0.06%)

As of 11:01 AM Eastern

Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time